Skip to main content

IL-2 gene therapy for chronic hepatitis B virus infection

Project description

Gene therapy for chronic hepatitis

The hepatitis B virus (HBV) can cause cirrhosis and hepatocellular carcinoma, leading to one million deaths per year worldwide. Since the mechanisms underlying HBV persistence are poorly understood, there is no definitive cure, and current treatments aim to reduce the development of liver disease. The EU-funded 2LIVEr project is working on a novel strategy to reactivate the ineffective CD8+ T cell response towards the HBV based on the hepatocellular delivery of interleukin-2 (IL-2) by lentiviral vectors. This gene therapy approach will serve as a functional cure against chronic hepatitis B by activating the immune system against the virus.

Host institution

OSPEDALE SAN RAFFAELE SRL
Net EU contribution
€ 150 000,00
Address
Via Olgettina 60
20132 Milano
Italy
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
No data

Beneficiaries (1)

OSPEDALE SAN RAFFAELE SRL
Italy
Net EU contribution
€ 150 000,00
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
No data